Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations.

ABSTRACT: Half of all cancer patients receive radiotherapy, which makes a substantial contribution to their long-term disease control/cure. There are significant inter-patient differences in response, both in terms of efficacy and toxicity (frequently delayed onset) which are difficult to predict. With the introduction of technological improvements (e.g. stereotactic body radiotherapy and proton therapy) and development of combination therapies (e.g. radiotherapy and immune checkpoint inhibition), predictive biomarkers are needed even more. Whilst genomic studies have contributed significantly to predictions of response to anticancer therapy, there is no doubt that more information can be gathered from patient tissue samples. Patients are willing to donate their tissues to biobanks and wish them to

SUBMITTER: Ward TH 

PROVIDER: S-EPMC8682944 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature